Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas—a meta-analysis
AbstractBackground. Chemo-immunotherapy is standard of care for women with recurrent or advanced mismatch repair deficient endometrial carcinoma. However,